ESMO 2024 Conference Review – Lung Cancer Focus
In this review:
– LAURA: CNS and distant progression results
– ALINA: exploratory biomarker analyses
– Adjuvant durvalumab in early stage, completely resected NSCLC
– RELATIVITY-104: first-line nivolumab + relatlimab + platinum-doublet chemotherapy for NSCLC
– PIONeeR: overcoming resistance to anti-PD(L)-1 in advanced NSCLC
– ALKOVE-1: a fourth-generation ALK inhibitor for ALK+ solid tumours
– REZILIENT1: zipalertinib in NSCLC with EGFR exon 20 insertion mutations after progression with amivantamab
– PRT3789: A novel SMARCA2 degrader in advanced solid tumours with SMARCA4 mutations
– ARROS-1: zidesamtinib in ROS1 fusion-positive solid tumours
– PECATI: lenvatinib + pembrolizumab in pretreated advanced B3-thymoma & thymic carcinoma
Expert contributor
Dr Aileen Ludlow
Aileen Ludlow is a medical oncologist at Auckland Public Hospital specialising in the management of Lung and GI cancer. She completed her oncology training in Christchurch before going on to do a research fellowship at the Royal Marsden Hospital in London. She is a principal and sub-investigator on several industry and collaborative group trials. She […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.
